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Abstract
Introduction: The GenoType system (HAIN Lifescience, Germany) offers new perspectives of detecting the tuberculous and
non-tuberculous mycobacteria at the molecular level. The system compromises five independent tests that could be per-
formed either on direct specimens or isolated strains, to identify the strains and test the resistance against rifampin and
isoniazid. Up to now, non GenoType test was applied in Poland. The aim of the study was an evaluation the accuracy of
GenoType MTBC test in speciation of the clinical isolates, previously classified as M. tuberculosis complex by HPLC analyze
of mycolic acids.
Material and methods: 161 clinical isolates, derived from the TB patients hospitalized in the Warsaw Medical University
Hospital between 1999 and 2007 were assayed.
Results: On the basis of the hybridization patterns, all 161 studied strains were identified as M. tuberculosis/M. canettii.
Conclusions:
1. The GenoType MTBC test (HAIN Lifescience, Germany) precisely recognizes M. tuberculosis complex. The 100% accor-
dance in speciation of M. tuberculosis by the GenoType MTBC test as compared to HPLC method was demonstrated. The
GenoType MTBC test can replace HPLC in detection of tuberculous mycobacteria in clinical isolates.
2. As the GenoType MTBC test performs well, the other tests of GenoType system may be considered to be verified in
diagnostic procedure of mycobacterial infection.
Key words: hybridization, multiplex PCR, Mycobacterium tuberculosis complex
Pneumonol. Alergol. Pol. 2009; 77: 517–520
Introduction
Nowadays, molecular biology techniques are
intensively used in the laboratory diagnostics of
tuberculosis, both in direct examination of speci-
mens, as well as in order to identify the species of
mycobacteria isolates. In studies of direct speci-
mens, commercial diagnostic kits, such as MTD
(GenProbe Inc. USA) or Amplicor MTB system
(Roche Diagnostics, USA), which apply nucleic
acid amplification reactions, are used to detect the
genetic material of Mycobacterium tuberculosis
complex. For typing isolates, highly specific nuc-
leic acid hybridization reaction is applied. The
most commonly accepted commercial system ap-
plying this method is AccuProbe (GenProbe Inc.
USA), which offers specially designed DNA pro-
bes for M. avium, M. gordonae, M. intracellulare,
M. kansasii and M. tuberculosis complex.
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Set of five probes of AccuProbe genetic sys-
tem usually allows for an effective diagnosis in the
routine procedure. However, it is not possible for
this molecular system to replace the high-perfor-
mance liquid chromatography (HPLC) in typing the
mycobacteria finally. The HPLC, which is based
on an analysis of mycolic acids, allows the typing
of more than 50 mycobacteria species, depending
on the range of reference strains in the laboratory
[1]. The only serious limitation of this method is
a very high cost of equipment and disposal of orga-
nic solvents. In addition, some closely related spe-
cies, having a similar set of mycolic acids, are in-
distinguishable by HPLC, for example within the
M. tuberculosis complex (except the M. bovis BCG).
For the comprehensive diagnosis of various
mycobacteria infections, a new molecular system,
GenoType Mycobacterium (HAIN Lifecience, Ger-
many) has been developed, which may replace the
chromatography in routine diagnostic procedure.
The GenoType Mycobacterium comprises five in-
dependent tests, but there is no need to perform
all of them. The advantage of the system is such
that the assays can be applied either separately or
in combination, depending on the demand.
• GenoType Mycobacteria Direct test, directly
applied to the clinical specimens, identifies
five species of mycobacteria: M. avium, M. in-
tracellulare, M. kansasii, M. malmoense and
M. tuberculosis complex [2].
• The tests GenoType Mycobacterium CM for
common mycobacteria, and GenoType Myco-
bacterium AS for additional species, which
can be performed together, enable to identify
30 types of mycobacterial strains [3].
• GenoType MTBC test is intended for the dif-
ferentiation of members of the M. tuberculosis
complex and particularly the identification of
M. bovis, which is not possible using HPLC [4].
• GenoType MTBDRplus, which has been deve-
loped to detect drug resistance to rifampicin
and isoniazid, can be applied not only to the
mycobacterial strains, but also to the direct
clinical specimens, provided they are AFB
positive [5]. Implementation the GenoType
MTBDRplus into the routine laboratory work
up would greatly accelerate the detection of
multidrug resistant strains.
Before the implementation of the GenoType
Mycobacterium system into the routine laborato-
ry diagnostic procedure of mycobacterial infection,
the accuracy of the individual tests needs to be
verified, both in terms of typing precision, as well
as in respect to the complexity execution. Accor-
ding to the authors’ knowledge, none of the tests
of GenoType system has been used so far in the
diagnostics of tuberculosis in Poland.
First, we have chosen the GenoType MTBC,
which provides a rapid and accurate identification
of the presence of various members of the M. tu-
berculosis complex (M. africanum, M. bovis BCG,
M. bovis ssp. bovis, M. bovis ssp. caprae, M. micro-
ti, M. tuberculosis/ M. canetti) when it is used with
growth-positive cultures. The assay is based on the
detection of single nucleotide polymorphism of the
gyrase B gene [6], and the Region of Difference 1
(RD1) deletion of M. bovis BCG [7]. Specific oligo-
nucleotides targeting these sequences are immobi-
lized on membrane strips. Amplicons derived from
a multiplex PCR hybridize to these probes. Species
can be identified according to the interpretation
chart provided by the manufacturer. Although the
assay does not provide tools for the differentiation
M. tuberculosis from M. canetti, there is a poor
chance to isolate M. canetti in Poland as this no-
vel pathogenic taxon of the MTBC has been descri-
bed recently, and rare cases have been reported in
patients living in Africa [8].
In this retrospective work, we evaluated the
GenoType MTBC assay to test a large number of
clinically significant isolates, using HPLC-based
mycolic acids analysis as a reference method. The
strains were derived from patients of The Central
Clinical Hospital of The Medical University of
Warsaw between 1999 and 2007.
Material and methods
Strains analyzed
A set of 161 M. tuberculosis complex strains,
isolated from pulmonary or extrapulmonary spe-
cimens (70 sputum, 52 bronchial washings, 14 bron-
chioalveolar lavage fluids, 13 pleural effusions,
6 pleural tissue samples and 6 others) were analy-
zed. Only one specimen per patient was used in
the present analysis. The specimens were initially
processed according to national guidelines [9]
using an N-acetyl-L-cysteine-NaOH decontamina-
tion procedure, inoculated onto solid slant media
(Löwenstein-Jensen), and incubated at 37°C for up
to 8 weeks. The clinical strains were typed with
HPLC based mycolic acids fingerprinting according
to the procedure being routinely performed in our
laboratory, as described previously [10]. Only spe-
cimens with growing tuberculosis bacteria were in-
cluded in the study.
GenoType MTBC assay
For an isolation of DNA, 1 loopful of bacteria
was suspended in distilled water (500 µl) and sub-
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jected to isolation procedure performed with AM-
PLICOR Respiratory Specimen Preparation Kit,
(Roche Diagnostics, USA), according to the manu-
facture’s instruction. The GenoType MTBC assay
was performed as recommended by the manufac-
turer. Briefly, for an amplification, 35 µl of a pri-
mer nucleotide mixture (provided with the kit), am-
plification buffer containing 1.5 mM MgCl2 and
1 U of Platinum Taq polymerase (Invitrogen, USA)
(not provided with the kit), and 10 µl of DNA in
a final volume of 55 µl were used. The amplification
protocol consisted of 300 s of denaturation at 95°C,
followed by 10 cycles comprising 30 s at 95°C and
120 s at 58°C, an additional 20 cycles comprising
25 s at 95°C, 40 s at 53°C, and 40 s at 70°C, and
a final extension at 70°C for 480 s.
Hybridization and detection were carried out
in a TwinCubator washing and shaking device
(HAIN Lifescience, Germany). The GenoType
MTBC assay was performed as recommended by
the manufacturer, and the species were identified
according to the interpretation chart provided with
the kit. Only those strips, that developed both con-
trol bands, UC (Universal Control) and CC (Con-
jugate Control), were regarded as interpretable. The
GC (Genus Control) reaction zone of the membra-
ne strip, which hybridizes with amplicons gene-
rated from all members of the M. tuberculosis com-
plex, should be positive for the whole set of stu-
died strains.
Results
Amplification and hybridization controls (UC
and CC, respectively) verified the test procedures:
All GenoType MTBC assays gave unequivocal re-
sults and none of the amplification reactions were
inhibited. All of the 161 specimens investigated
showed the pattern M. tuberculosis/M. canettii. The
identification results for all specimens were in
complete accordance with the previous differen-
tiation results obtained by HPLC.
The GenoType MTBC assay fits easily into the
work flow of a routine laboratory, provided the
basic equipment for molecular biology assays is
accessible and can be completed within 5 hours
for 12 specimens.
Discussion and conclusion
The GenoType MTBC assay has been CE mar-
ked for the use in Europe for several years and some
authors have already evaluated the accuracy of the
test in clinical practice [4, 11–13]. The authors gene-
rally emphasize that the GenoType MTBC assay is an
easy-to-use and reliable method for the routine iden-
tification of members of the M. tuberculosis complex.
The assay could be implemented in any mycobacte-
riology laboratory in order to speed up the mycobac-
terial diagnostics. Richter et al. [11] compared the
GenoType MTBC assay with the AccuProbe test. The
sensitivity was slightly higher for the GenoType
MTBC test than for the AccuProbe assay (100% and
97.4%, respectively). Somoskovi et al. [13] noticed
the high sensitivity (93.2%) and specificity (100%)
of the GenoType MTBC assay when used directly on
a set of 79 smear-positive clinical specimens.
The goal of the present study was to evaluate
the GenoType MTBC assay in practice, in our lo-
cal laboratory. We have chosen this test to be veri-
fied as the first one from the GenoType system
(HAIN Lifescience, Germany) for the tuberculosis
sake and on grounds of positive opinions cited
above. A set of 161 clinical isolates of M. tubercu-
losis complex was analyzed using HPLC-based
mycolic acids analysis as a reference method. Yiel-
ded results were absolutely in concordance.
From a practical point of view, the GenoType
MTBC assay has several advantages. First, as it is
a molecular biology based technique, the total cost
of species differentiating is much lower then the
cost of using a HPLC method, while the expense
of sophisticated equipment is very high and the uti-
lization of organic solvents is even much more
higher. The GenoType system demands basic equip-
ment, easily accessible at a routine laboratory,
and the price of the assay is comparable to other
molecular tests used in Poland. Second, it takes
5 hours to complete the assay for a set of 12 speci-
mens. On the contrary, the HPLC analysis is much
more time consuming. Third, thanks to control
bands put on each hybridization strip, there is no
need to perform the whole set of 12 assays at the
time. In consequence, each specimen could be as-
sayed on demand, which does not influence the
price of the test.
Considering the laboratory diagnosis of tuber-
culosis, the HPLC technique, which has been used
for detecting M. tuberculosis complex isolates up
to date, could be substituted with the GenoType
MTBC assay without difficulty. However, the as-
say does not address the nontuberculous mycobac-
teria differentiation. Other tests of the GenoType
system could easily be applied to eliminate this dis-
advantage without spending extra money for new
equipment [3]. In this situation, some new bene-
fits would be observed: The AFB positive clinical
specimens could be examined directly along with
the drug susceptibility testing to rifampicin and
isoniazid [2, 5].
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